3.9 Article

Best Clinical Practices with ATX-101 for Submental Fat Reduction: Patient-related Factors and Physician Considerations

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/GOX.0000000000003668

关键词

-

类别

资金

  1. Allergan Aesthetics, an AbbVie Company, Dublin, Ireland
  2. Allergan Aesthetics, an AbbVie Company

向作者/读者索取更多资源

ATX-101, a customizable and minimally invasive alternative to liposuction, can reduce submental fat. An expert panel provided best practices for the use of ATX-101 in submental contouring, covering patient selection, managing expectations, and administration guidance. These best clinical practices aim to enhance the patient treatment experience and outcomes.
Background: Submental fat can be reduced with ATX-101 (deoxycholic acid injection), a customizable and minimally invasive alternative to liposuction. In the years since its approval, the treatment patterns of ATX-101 have evolved. Methods: A panel of experienced physicians from the United States gathered to generate best practices for the use of ATX-101 in submental contouring. Results: The expert panel provided their insights on appropriate patient selection, managing patient expectations of ATX-101 treatment outcomes, and adverse events, and guidance on ATX-101 administration for optimal outcomes are presented here. Conclusion: These best clinical practices on the use of ATX-101 for the reduction of submental fat should enable physicians to enhance the patient treatment experience and outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据